| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit(mg) | Dosage Form | Pack Size(in ml) | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.5.3.1 | Phenytoin Sodium Injection | Sara Pharmaceuticals | -- | 50 | Injection | 2 | 4.18 | 959937 | 100.00% | 2.09 |
| -- | Monopoly situation as only M/s. Sara Pharma | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | 25 mg/ml | 2.09 | -- | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
5.5: Anticonvulsants/ Antiepileptics
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Phenytoin Sodium | P,S, T | Injection | 50 mg/ml | 5.15 | 8th | 3329 | 05.11.2013 | 10.48% |
| -- | -- | -- | -- | -- | -- | -- | Average Reduc | -- | 10.48% |
| -- | Therefore, PTR per unit | 2.09x(1-10.48%) | 1.87 | -- | -- | -- | -- | -- | |
| -- | Add: 16% Retailer Margin | -- | 0.30 | -- | -- | -- | -- | -- | |
| -- | Ceiling Price per unit | -- | 2.17 | -- | -- | -- | -- | -- | |
| -- | WPI factor @ 6.32% | -- | 0.14 | -- | -- | -- | -- | -- | |
| -- | Ceiling Price (including WPI but without local taxes) | 2.31 | S.O. 2089(E) dat | -- | -- | -- | -- | ||
| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit | Dosage Form | Pack Size(in gm) | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.2.0.4 | Neomycin + Bacitracin | Crescent Labs ltd. | Vetbacin Ointm | Gm | Ointment | 20 | 31.57 | 9243696 | 100.00% | 1.58 |
| -- | Monopoly situation as only M/s. Crescent Lab | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | 1.58 | -- | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | 13.2: Antiinfective medicines | -- | -- | -- | -- | |||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Acyclovir | S, T | Cream | 5% | 8.88 | 2nd | 1812 | 21.06.2013 | 34.22 |
| 2 | Framycetin Sulphate | P,S,T | Cream | 0.50% | Data not yet available | -- | -- | -- | -- |
| 3 | Methylrosanilinium Chloride (Gentian Violet) | P,S,T | Aqueous solution | 0.50% | Data not yet available | -- | -- | -- | -- |
| 4 | Neomycin + Bacitracin | P,S,T | Ointment | 5 mg + 500 IU / g | Under consideration | -- | -- | -- | -- |
| 5 | Povidone Iodine | P,S,T | Solution | 5% | 0.39 | 1st | 1651 | 14.06.2013 | 69.14 |
| 6 | Povidone Iodine | P,S,T | Ointment | 5% | 1.64 | 3rd | 1905 | 28.06.2013 | 57.89 |
| 6 | Silver Sulphadiazine | P,S,T | Cream | 1% | Data not yet available | -- | -- | -- | -- |
| -- | -- | -- | -- | -- | Average Reduction | -- | Average Reduction | 53.75 | |
| -- | Therefore, PTR per unit | 1.58X (1-53.75%) | 0.73 | -- | -- | -- | -- | -- | |
| -- | Add: 16% Retailer Margin | -- | 0.12 | -- | -- | -- | -- | -- | |
| -- | Ceiling Price per unit | -- | 0.85 | -- | -- | -- | -- | -- | |
| -- | WPI factor @ 6. | -- | -- | 0.05 | -- | -- | -- | -- | -- |
| -- | Ceiling Price (including WPI but without local taxes) | 0.90 | S.O. 2087 | -- | -- | -- | -- | ||
| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit | Dosage Form | Pack Size | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 21.5.0.3 | Phenylephrine Drop | Auro Lab | Aurophenyl | ml | Drops | 5 | 28.00 | 57457 | 100.00% | 5.60 |
| -- | Monopoly situation as only M/s. Auro Lab. is t | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | 5.60 | -- | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | 21.5 : Mydriatics | -- | -- | -- | -- | |||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Atropine Sulphate | P,S,T | Drops | 1% | 2.91 | 2nd | 1830 | 21.06.2013 | 34.71 |
| 2 | Atropine Sulphate | P,S,T | Ointment | 1% | 3.24 | 2nd | 1831 | 21.06.2013 | 27.44 |
| 3 | Homatropine | P,S,T | Drops | 2% | 5.44 | 9th | 3573 | 02.12.2013 | 22.52 |
| 4 | Phenylephrine | P,S,T | Drops | 5% | Under Consideration | -- | -- | -- | -- |
| -- | -- | -- | -- | -- | -- | -- | Average Reduction | 28.22 | |
| -- | Therefore, PTR per unit | 5.60X (1-28.22%) | 4.02 |
-- |
|||||
| -- | Add: 16% Retailer Margin | -- | 0.64 |
-- |
|||||
| -- | Ceiling Price per unit | -- | 4.66 |
-- |
|||||
| -- | WPI factor @ 6. | -- | -- | 0.29 |
-- |
||||
| -- | Ceiling Price (including WPI but without local taxes) | 4.95 | S.O. 2088 |
-- |
|||||
| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit | Dosage Form | Pack Size | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 14.2.8.1 | Sodium Meglumine Diatrizoate 60% | Arco Lifesciences (I) Pvt. Ltd. | -- | ml | Injection | 20 | 114.69 | 393700 | 92.55% | 5.73 |
| 14.2.8.1 | Sodium Meglumine Diatrizoate 60% | Arco Lifesciences (I) Pvt. Ltd. | -- | ml | Injection | 50 | 271.40 | 31680 | 7.45% | 5.43 |
| -- | Monopoly situation as only M/s. Arco Lifescie | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | 5.58 | -- | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Section: 14 –Diagnostic agents |
-- |
||||||||
| -- | 14.1: Ophthalmic medicines |
-- |
||||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Fluorescein | S, T | Eye drops | 1% | Data Not Available | -- | -- | -- | -- |
| -- | Lignocaine | S, T | Eye Drops | 4% | Data Not Available | -- | -- | -- | -- |
| -- | Tropicamide | S, T | Eye drops | 1% | 9.60 | 1st | 1650 | 14.06.2013 | 28.52 |
| -- | 14.2: Radiocontrast media | -- | -- | -- | -- | -- | |||
| -- | Barium Sulphate | S, T | Suspension | 100% w/v | Data Not Available | -- | -- | -- | -- |
| -- | Barium Sulphate | S, T | Suspension | 250% w/v | Data Not Available | -- | -- | -- | -- |
| -- | Calcium Ipodate | S, T | Injection | 3 g | Data Not Available | -- | -- | -- | -- |
| -- | Iopanoic Acid | S, T | Tablets | 500 mg | Data Not Available | -- | -- | -- | -- |
| -- | Meglumine Iothalamate | S, T | Injection | 60% w/v (iodine =280 mg / ml) | Data Not Available | -- | -- | -- | -- |
| -- | Meglumine Iotroxate | S, T | Solution | 5-8 g iodine in 100-250 ml | Data Not Available | -- | -- | -- | -- |
| -- | Propyliodone | S, T | Oily, suspension | 500-600 mg / ml | Data Not Available | -- | -- | -- | -- |
| -- | Sodium Iothalamate | S, T | Injection | 70% w/v(Iodine =420 mg / ml) | Data Not Available | -- | -- | -- | -- |
| -- | Sodium Meglumine Diatrizoate | S, T | Injection | 60% w/v(Iodine conc. =292 mg / ml) | Under consideration | -- | -- | -- | -- |
| -- | Sodium Meglumine Diatrizoate | S, T | Injection | 76% w/v(Iodine conc. =370 mg / ml) | Under consideration | -- | -- | -- | -- |
| -- | -- | -- | -- | -- | -- | Average Reduction | 28.52 | ||
| -- | Therefore, PTR per unit | 5.58X (1-28.52%) | 3.99 | -- | -- | -- | -- | -- | |
| -- | Add: 16% Retailer Margin | -- | 0.64 | -- | -- | -- | -- | -- | |
| -- | Ceiling Price per unit | -- | 4.63 | -- | -- | -- | -- | -- | |
| -- | WPI factor @ 6.32% | -- | -- | 0.29 | -- | -- | -- | -- | -- |
| -- | Ceiling Price (including WPI but without local taxes) | 4.92 | S.O. 2092(E) dat | -- | -- | -- | -- | ||
| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit | Dosage Form | Pack Size | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 14.2.8.2 | Sodium Meglumine Diatrizoate 76% | Arco Lifesciences (I) Pvt. Ltd. | -- | ml | Injection | 20 | 137.59 | 1622400 | 60.96% | 6.88 |
| 14.2.8.2 | Sodium Meglumine Diatrizoate 76% | Arco Lifesciences (I) Pvt. Ltd. | -- | ml | Injection | 50 | 318.24 | 1039080 | 39.04% | 6.36 |
| -- | -- | -- | -- | -- | -- | -- | -- | 2661480 | 100.00% | 6.62 |
| -- | Monopoly situation as only M/s. Arco Lifescie | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | 6.62 | -- | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Section: 14 –Diagnostic agents |
-- |
||||||||
| -- | 14.1: Ophthalmic medicines |
-- |
||||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Fluorescein | S, T | Eye drops | 1% | Data Not Available | -- | -- | -- | -- |
| -- | Lignocaine | S, T | Eye Drops | 4% | Data Not Available | -- | -- | -- | -- |
| -- | Tropicamide | S, T | Eye drops | 1% | 9.60 | 1st | 1650 | 14.06.2013 | 28.52 |
| -- | 14.2: Radiocontrast media | -- | -- | -- | -- | -- | |||
| -- | Barium Sulphate | S, T | Suspension | 100% w/v | Data Not Available | -- | -- | -- | -- |
| -- | Barium Sulphate | S, T | Suspension | 250% w/v | Data Not Available | -- | -- | -- | -- |
| -- | Calcium Ipodate | S, T | Injection | 3 g | Data Not Available | -- | -- | -- | -- |
| -- | Iopanoic Acid | S, T | Tablets | 500 mg | Data Not Available | -- | -- | -- | -- |
| -- | Meglumine Iothalamate | S, T | Injection | 60% w/v (iodine =280 mg / ml) | Data Not Available | -- | -- | -- | -- |
| -- | Meglumine Iotroxate | S, T | Solution | 5-8 g iodine in 100-250 ml | Data Not Available | -- | -- | -- | -- |
| -- | Propyliodone | S, T | Oily, suspension | 500-600 mg / ml | Data Not Available | -- | -- | -- | -- |
| -- | Sodium Iothalamate | S, T | Injection | 70% w/v(Iodine =420 mg / ml) | Data Not Available | -- | -- | -- | -- |
| -- | Sodium Meglumine Diatrizoate | S, T | Injection | 60% w/v(Iodine conc. =292 mg / ml) | 4.63 | Proposed | 28.52 | ||
| -- | Sodium Meglumine Diatrizoate | S, T | Injection | 76% w/v(Iodine conc. =370 mg / ml) | Under consideration | -- | -- | -- | -- |
| -- | -- | -- | -- | -- | -- | Average Reduction | 28.52 | ||
| -- | Therefore, PTR per unit | 6.62X (1-28.52%) | 4.73 | -- | -- | -- | -- | -- | |
| -- | Add: 16% Retailer Margin | -- | 0.76 | -- | -- | -- | -- | -- | |
| -- | Ceiling Price per unit | -- | 5.49 | -- | -- | -- | -- | -- | |
| -- | WPI factor @ 6.32% | -- | -- | 0.35 | -- | -- | -- | -- | -- |
| -- | Ceiling Price (including WPI but without local taxes) | 5.84 | S.O. 2092(E) dat | -- | -- | -- | -- | ||
| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit | Dosage Form | Pack Size | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.1.5.1 | Pyridoxine Tablet 10 mg | Vikas Pharmaceuticals Laboratories | -- | Tablet | Tablet | 1000 | 100.00 | 100000 | 20.04% | 0.10 |
| -- | -- | Vikas Pharmaceuticals Laboratories | -- | Tablet | Tablet | 200 | 114.00 | 399000 | 79.96% | 0.57 |
| -- | -- | -- | -- | -- | -- | -- | -- | 499000 | 100.00% | 0.34 |
| -- | Monopoly situation as only M/s. Vikas Pharma | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | 0.34 | -- | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | 10.1 Antianaemia Medicines | -- | -- | -- | -- | -- | ||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Cyanocobalamin | P, S,T | Injection | 1 mg/ml | No Data | -- | -- | -- | -- |
| -- | Ferrous Sulphate/Fumrate | P,S,T | Tablets | Tablets equivalent to 60 mg elemental iron | No Data | -- | -- | -- | -- |
| -- | Ferrous Sulphate/Fumrate | P,S,T | Oral solution | 25mg elemental iron (as sulphate)/ml | No Data | -- | -- | -- | -- |
| -- | Folic Acid | P,S,T | Tablets | 1 mg | 0.25 | 8th meeti | 3365 | 05.11.2013 | 48.07 |
| -- | Folic Acid | P,S,T | Tablets | 5mg | 1.37 | 9th meeti | 3570 | 02.12.2013 | 38.02 |
| -- | Iron Dextran | S, T | Injection | 50 mg iron/ml | 28.71 | 5th meeti | 2245 | 22.07.2013 | 57.46 |
| -- | Pyridoxine | P,S,T | Tablets | 10 mg | Under Consideration | -- | -- | -- | -- |
| -- |
-- |
-- | -- | -- | -- | Average Reduction | 47.85 | ||
| -- | Therefore, PTR per unit | 0.34X (1-47.85%) | 0.18 |
-- |
-- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.03 |
-- |
-- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 0.21 |
-- |
-- | -- | -- | ||
| -- | WPI factor @ 6.32% | -- | -- | 0.01 |
-- |
-- | -- | -- | |
| -- | Ceiling Price (including WPI but without local taxes) | 0.22 | S.O. 2091(E) dat | -- | -- | -- | -- | ||
| Unique No. as per NLEM | Composition as per NLEM | Company | Brands | Unit | Dosage Form | Pack Size | Price to Retailer | MAT Value as on 31st May 2012 | MAT % | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.1.0.5 | Polygeline | Abbott Healthcare Pvt. Ltd | -- | ml | Injection | 500 | 244.66 | 375084000 | 100% | 0.49 |
| -- | Monopoly situation as only Abbott Health | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | -- | 0.49 | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Dextran-40 | P,S,T | Injection | 10% | 0.75 | 8th | 3344 | 05.11.2013 | 12.47 |
| -- | Dextran-70 | P,S,T | Injection | 6% | No Data | -- | -- | -- | -- |
| -- | Fresh frozen plasma | T | Injection | -- | No Data | -- | -- | -- | -- |
| -- | Hydroxyethyl Starch (Hetastarch) | S, T | Injection | 6% | 0.74 | 8th | 3366 | 05.11.2013 | 12.47 |
| -- | Polygeline | S, T | Injection | 3.50% | Under Consideration | -- | -- | -- | -- |
| -- | -- | -- |
-- |
Average Reduction | 12.47 | -- |
-- |
||
|
-- |
|||||||||
| -- | Therefore, PTR per unit | 0.49X (1-12.47%) | 0.43 |
-- |
|||||
| -- | Add: 16% Retailer Margin | -- | 0.07 |
-- |
|||||
| -- | Ceiling Price per unit | -- | 0.50 |
-- |
|||||
| -- | WPI factor @ 6.32% | -- | -- | 0.03 |
-- |
||||
| -- | Ceiling Price (including WPI but without local taxes) | 0.53 | S.O. 2090(E) dat |
-- |
|||||
| Unique No. as per NLEM | Composition as per NLEM | Pack Descripti | BRANDS | Company | Strength | Pack Siz | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.1.1.1 | Chlorpromazine hydrochloride Tablets 25 | CPZ FILM C.TA | CPZ | A.N.PHARMA | 25 | 10 | TABS | 2344440 | 68.07% | 2.22 | 0.22 | -- |
| -- | Chlorpromazine hydrochloride Tablets 25 mg | EMETIL TABS 2 | EMETIL | LA PHARMA | 25 | 10 | TABS | 984237 | 28.58% | 2.42 | 0.24 | -- |
| -- | Chlorpromazine hydrochloride Tablets 25 mg | RELITIL FILM C. | RELITIL | RELIANCE LI | 25 | 10 | TABS | 115520 | 3.35% | 2.31 | 0.23 | -- |
| -- | -- | -- | -- | -- | -- | -- | -- | 3444197 | 100.00% | -- | 0.23 | 0.27 |
| -- | -- | -- | -- | -- | -- | -- | -- | maximum | 0.24 | minimum | 0.22 | -- |
| -- | As per the above there are 3 companies c | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Sum of MAT value considered for price ca | -- | -- | 34.44 | (Rs. In Lakhs) | -- | -- | -- | -- | -- | -- | -- |
| -- | Sum of PTR per unit considered for price | -- | -- | 0.69 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Number of Packs considered | -- | -- | 3 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Ceiling Price | -- | -- | 0.23 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Add : 16% Retailer Margin | -- | -- | 0.04 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | MRP (without local taxes) | -- | -- | 0.27 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | % Reduction with compared to Highest Pr | -- | -- | 4.17% | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | WPI factor @ 6.32% | -- | -- | 0.02 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Revised Ceiling Price(including W | -- | -- | 0.29 | S.O. 2094(E) dat | -- | -- | -- | -- | -- | -- | -- |
| Unique No. as per NLEM | Composition as per NLEM | Pack Descripti | BRANDS | Company | Strength | Pack Siz | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.2.1.4.1 | Cefotaxime Injection 125 mg | BIOTAX VIAL D | BIOTAX | ZYDUS CADI | 125 | 1 | -- | 9673777 | 12.00% | 10.81 | 10.81 | -- |
| -- | Cefotaxime Injection 125 mg | C-TAX INJ DRY | C-TAX | EMCURE* | 125 | 1 | -- | 2366813 | 2.94% | 10.71 | 10.71 | -- |
| -- | Cefotaxime Injection 125 mg | CEFANTRAL VI | CEFANTRAL | LUPIN LIMITE | 125 | 1 | -- | 656051 | 0.81% | 9.72 | 9.72 | -- |
| -- | Cefotaxime Injection 125 mg | CEFANTRAL IN | CEFANTRAL | LUPIN LIMIT | 125 | 1 | -- | 259480 | 0.32% | 9.72 | 9.72 | -- |
| -- | Cefotaxime Injection 125 mg | OMINAX INJ DR | OMINAX | MAPRA LAB | 125 | 1 | -- | 2684813 | 3.33% | 10.22 | 10.22 | -- |
| -- | Cefotaxime Injection 125 mg | TAXIM VIAL DR | TAXIM | ALKEM* | 125 | 1 | -- | 62978703 | 78.13% | 10.98 | 10.98 | -- |
| -- | Cefotaxime Injection 125 mg | OMNICEF INJ D | OMNICEF | ARISTO PHA | 125 | 1 | -- | 1988666 | 2.47% | 10.71 | 10.71 | -- |
| -- | -- | -- | -- | -- | -- | -- | -- | 80608303 | 100.00% | -- | 10.41 | 12.08 |
| -- | -- | -- | -- | -- | -- | -- | -- | maximum | 10.98 | minimum | 9.72 | -- |
| -- | As per the above there are 6 companies c | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Sum of MAT value considered for price ca | -- | -- | 806.08 | (Rs. In Lakhs) | -- | -- | -- | -- | -- | -- | -- |
| -- | Sum of PTR per unit considered for price | -- | -- | 72.87 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Number of Packs considered | -- | -- | 7 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Ceiling Price | -- | -- | 10.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Add : 16% Retailer Margin | -- | -- | 1.67 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | MRP (without local taxes) | -- | -- | 12.08 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | % Reduction with compared to Highest Pr | -- | -- | 5.19% | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | WPI factor @ 6.32% | -- | -- | 0.76 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Revised Ceiling Price(including W | -- | -- | 12.84 | S.O. 2093(E) dat | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- |
-- |
-- | -- | -- | ||||||
| – | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling Price with 16% Margin | – |
| -- | SYNDOPA TAB UNCOATED 100 M | SYNDOPA | SUN* | 100 | 10 | TABS | 68761083 | 93.89% | 13.6 | 1.36 | -- | -- |
| -- | TIDOMET TABS L.S 100 MG x 10 (/1 | TIDOMET | TORRENT | 100 | 10 | TABS | 4472436 | 6.11% | 12.36 | 1.24 | -- | -- |
| -- | -- | -- | -- | -- | -- | -- | 73233519 | 100.00% | -- | 1.30 | 1.51 | -- |
| -- | -- | -- | -- | -- | -- | -- | maximum | 1.36 | minimum | 1.24 | -- | -- |
| -- | -- | -- | 732.34 | (Rs. In Lak | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 2.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 2 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 1.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 0.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 1.51 | Earlier S.o. | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 4.41% | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 0.10 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | 1.61 | S.O. 2095(E) |
-- |
-- | -- | |||||
| -- | -- | -- |
-- |
-- | -- | -- | ||||||
| – | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling Price with 16% Margin | – |
| -- | LCD TAB UNCOATED 100 MG x 10 (/25) | LCD | INTAS PHAR | 100/25 | 10 | TABS | 1448413 | 0.95% | 17.21 | 1.72 | -- | -- |
| -- | SYNDOPA TABS PLUS 100 MG x 10 (/25) | SYNDOPA | SUN* | 100/25 | 10 | TABS | 129727536 | 84.90% | 18.9 | 1.89 | -- | -- |
| -- | SYNDOPA TABS CR 100 MG x 10 (/25) | SYNDOPA | SUN* | 100/25 | 10 | TABS | 10708407 | 7.01% | 17.34 | 1.73 | -- | -- |
| -- | TIDOMET TABS PLUS 100 MG x 10 (/25) | TIDOMET | TORRENT P | 100/25 | 10 | TABS | 10913296 | 7.14% | 18.98 | 1.90 | -- | -- |
| -- | -- | -- | -- | -- | -- | -- | 152797652 | 100.00% | -- | 1.84 | 2.13 | -- |
| -- | -- | -- | -- | -- | -- | -- | maximum | 1.90 | minimum | 1.73 | -- | -- |
| -- | -- | 1,513.49 | (Rs. In Lak | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 5.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 1.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 0.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 2.13 | Earlier, S. | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 3.16% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 0.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 2.26 | S.O. 2095(E) d | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|
| SYNDOPA TAB UNCOATED 250 M | SYNDOPA | SUN* | 250 | 10 | TABS | 36465035 | 81.00% | 32.7 | 3.27 | -- |
| TIDOMET TABS FORT 250 MG x 10 | TIDOMET | TORRENT | 250 | 10 | TABS | 8552734 | 19.00% | 29.67 | 2.97 | -- |
| -- | -- | -- | -- | -- | -- | 45017769 | 100.00% | -- | 3.12 | 3.62 |
| -- | -- | -- | -- | -- | -- | maximum | 3.27 | minimum | 2.97 | -- |
| -- | -- | 450.18 | (Rs. In Lak | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 6.24 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 2 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 3.12 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 0.50 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 3.62 | Earlier, S.O | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 4.59% | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 0.23 | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | 3.85 | S.O. 2095(E) | -- | -- | -- | -- | -- | -- | -- |
Source of Data-IMS-Health November 2013
| S.No. | Composition of the formulation | Company | Dosage Form | Pack size | MAT Units | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet | Retail Price with 16 % Margin |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PYRALFIN TABS 25 MG x 2 (/500) | LUPIN LABS | Tablet | 2 | 6,184,711 | 3.04 | 18,802,107 | 42.12% | 1.52 | -- |
| 2 | PYRALFIN TAB UNCOATED 25 MG x 10 (/500) | LUPIN LABS | Tablet | 10 | 363,843 | 15.35 | 5,585,008 | 12.51% | 1.54 | -- |
| 3 | DARAMIN TABS 25 MG x 10 (/500) | INDICA | Tablet | 10 | 20,635 | 4.20 | 86,668 | 0.19% | 0.42 | -- |
| 4 | AMALAR TAB UNCOATED 25 MG x 2 (/500) | MICRO LABS | Tablet | 2 | 18,346 | 3.12 | 57,241 | 0.13% | 1.56 | -- |
| 5 | REZIZ TAB UNCOATED 500 MG x 2 (/25) | PLETHICO | Tablet | 2 | 3,717,547 | 3.42 | 11,941,269 | 26.75% | 1.71 | -- |
| 6 | LARIDOX TABS 500 MG x 2 (/25) | IPCA LABS | Tablet | 2 | 1,868,367 | 3.96 | 7,002,743 | 15.69% | 1.98 | -- |
| 7 | MALCIDAL TABS 500 MG x 3 (/25) | LARK LABS | Tablet | 3 | 188,107 | 4.64 | 893,184 | 2.00% | 1.55 | -- |
| 8 | MALARCE TAB UNCOATED 500 MG x 2 (/25) | GUJARAT TERC | Tablet | 2 | 15,401 | 16.35 | 251,805 | 0.56% | 8.18 | -- |
| 9 | META-FIN TAB UNCOATED 500 MG x 2 (/25) | -- | Tablet | 2 | 1,067 | 15.03 | 16,037 | 0.04% | 7.52 | -- |
| 10 | MALASULF TABS 500 MG x 2 (/25) | BOMBAY TABLE | Tablet | 2 | 1,411 | 2.55 | 3,598 | 0.01% | 1.28 | -- |
| -- | -- | -- | -- | -- | -- | -- | 44,639,660 | 100.00% | 1.66 | 1.93 |
| -- | -- | -- | -- | -- | -- | -- | Maximum | 1.98 | Minimum | 1.52 |
| -- | As per the above there are 4 companies consisting of Market Share of 1% & Above | -- |
-- |
|||||||
| -- | Sum of MAT value considered for price calculation |
-- |
442.24 | (Rs. in Lakhs) |
-- |
-- | ||||
| -- | Sum of PTR per unit considered for price calculation |
-- |
8.30 | -- |
-- |
|||||
| -- | Number of Packs considered | -- |
-- |
5 | -- |
-- |
||||
| -- | Ceiling Price | -- |
-- |
1.66 | -- |
-- |
||||
| -- | Add : 16% Retailer Margin | -- |
-- |
0.27 | -- |
-- |
||||
| -- | MRP (without local taxes) | -- |
-- |
1.93 | S.O. 2100 |
-- |
||||
| -- | % Reduction with compared to Highest Price |
-- |
16.16% | -- |
-- |
|||||
Source of Data-Company ( July, 2013)
| S.No. | Composition of the Product | Brand Nam | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500 mg (In sustained release form) Gliclazide IP 60 mg (In sustained release form) Pioglitazone Hydrochloride IP Eq. to Pioglitazone 7.5 mg Approved colours are used Excipiencts q.s |
Glizid Total P 7.5 | Panacea Biotec | Tablet | 10 | 53.90 | 1,024,000 | 100.00% | 5.39 |
| -- | -- | -- | -- | -- | -- | -- | 1,024,000 | #DIV/0! | #DIV/0! |
| -- | Monopoly situation as only M/s. | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | -- | 5.39 | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-s | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | 18.5: Medicines used in Diabetes mellitus |
-- |
|||||||
| -- | 18.5.1: Insulins and other Antidiabetic agents |
-- |
|||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Metformin | P,S,T | Tablets | 500mg | 1.56 | 2nd | 1814 | 21.6.2013 | 41.56 |
| -- | -- | -- | -- | -- | -- | -- | Average Reduction | 41.56 | |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Therefore, PTR per unit | 5.39x(1-41.56%) | 3.15 | -- | -- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.50 | -- | -- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 3.65 | S.O. 2101 | -- | -- | -- | ||
| Unique No. as per NLEM | Name of the Product | Composition of the Product | Company | Brands | Dosage Form | Pack Size | Price to Retailer | MAT Value as on 31st May 2013 | MAT % | Price per Tablet |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.1.2.1 & 2.2.0.2 | Tramadol and Diclofenac SR Tablets | Each film coated bilayered tablet contains: Tramadol HCL IP 50 mg diclofenac Sodium IP 75 mg (as sustained release layer) |
Abbott Healthcare Pvt. Ltd. | DURAPAIN tablets10’s | Tablets | 10 | 75.43 | 6428212 | 10000% | 7.54 |
| -- | Monopoly situation as only M/s. Abbott Healt | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | -- | 7.54 | -- | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-section for ot | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Section: 2 – Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders | -- | -- | -- | -- | |||||
| -- | 2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines | -- | -- | -- | -- | |||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Diclofenac | T | Tablets | 50 mg | 1.95 | 3rd | 1909(E) | 28.06.2013 | 52.64 |
| 2 | Diclofenac | T | Injection | 25 mg / ml | 1.49 | 7th | 2869(E) | 20.09.2013 | 70.44 |
| -- | 2.2 Opioid Analgesics | -- | -- | -- | -- | -- | |||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | |||||
|---|---|---|---|---|---|---|---|---|---|
| -- | Added medicines | -- | -- | -- | -- | -- | |||
| 3 | Tramadol | S,T | Injection | 50 mg/ml | 11.73 | 5th | 2231(E) | 22.07.2013 | 42.16 |
| 4 | Tramadol | S,T | Cap | 50 mg | 6.03 | 16th | 1788(E) | 10.07.2014 | 26.24 |
| 5 | Tramadol | S,T | Cap | 100 mg | Nil Data | -- | -- | -- | -- |
| -- | -- | -- | -- | -- | -- | -- | Average Reduction | 47.87 | |
| -- | Therefore, PTR per unit | 7.54x(1-47.87%) | 3.93 | -- | -- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.63 | -- | -- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 4.56 | S.O. 2102 | -- | -- | -- | ||
Source of Data-Companies data July, 2013
| Composition of the Product | Brand Name | Company | Dosage Form | Pack size(in ml) | Price to Retailer (Rs.) | MAT Value | MAT % | Price per ml |
|---|---|---|---|---|---|---|---|---|
| Each 5 ml Contains: Cetirizine HCL IP 2.5 mg Paracetamol IP 125 mg Phenylephrine HCL IP 2.5 mg Flavoured Syrup Base q.s colour : Sunset Yellow |
Belrin-D | Ms Globus Remedies Ltd./PDC Healthcare | Suspensio | 60 | 28.70 | 1,093,585 | 100.00% | 0.48 |
| Monopoly situation as only M/s. Gl | -- | -- | -- | -- | -- | -- | -- | -- |
| PTR per unit | -- | -- | 0.48 | -- | -- | -- | -- | -- |
| Price fixed in the relevant sub-sect | -- | -- | -- | -- | -- | -- | -- | -- |
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Section: 2 – Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders | -- | -- | -- | -- | ||||
| -- | 2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines | -- | -- | -- | -- | ||||
| -- | Paracetamol | P, S, T | Syrup | 125 mg / 5ml | 0.32 | 11th | 421 | 17.02.2014 | 30.00 |
| -- | -- | -- | -- | -- | f | -- | -- | -- | -- |
| -- | Section: 3 – Antiallergics and Medicines used in Anaphylaxis | -- | -- | -- | -- | ||||
| -- | Added Medicines | -- | -- | -- | -- | ||||
| -- | Cetrizine | P,S,T | Syrup | 5 mg/ml | 0.54 | 3rd | 1876 | 28.06.2013 | 56.48 |
| -- | Section: 21 – Ophthalmological Preparations | -- | -- | -- | -- | ||||
| -- | 21.5 Mydriatics | -- | -- | -- | -- | ||||
| -- | Phenylephrine | P,S,T | Drops | 5% | 4.66 | Proposed in 17th Meeting | 28.22 | ||
| -- | -- | -- | -- | -- | -- | -- | -- | Average Reduction | 38.23 |
| -- | Therefore, PTR per unit | 0.48x(1-28.22%) | 0.30 | -- | -- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.05 | -- | -- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 0.35 | S.O. 2103 | -- | -- | -- | ||
| Source of Data-IMS-Health July, 2013 | -- | -- | -- | -- | |||||
| Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per Tablet |
|---|---|---|---|---|---|---|---|---|
| Bisoprolol Fumarate & Amlodipine Besilate Tablets Each film coated tablet contains: Bisoprolol Fumarate U.S.P 5 mg Amlodipine Besilate I.P Eq. to Amlodipine 5 mg Excipients |
ZABESTA-A | USV | Tablet | 10 | 55.06 | 12,312,873 | 100.00% | 5.51 |
| Monopoly situation as only M/s. U | -- | -- | -- | -- | -- | -- | -- | -- |
| PTR per unit | -- | -- | 5.51 | -- | -- | -- | -- | -- |
| Price fixed in the relevant sub-sect | -- | -- | -- | -- | -- | -- | -- | -- |
| 12.3: Antihypertensive medicines | -- | -- | -- | -- | ||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| -- | Amlodipine | P,S,T | Tablets | 5 mg | 2.83 | 10th | 3773 | 20.12.2013 | 62.23 |
| -- | -- | -- | -- | -- | -- | -- | -- | Average Reduction | 62.23 |
| -- | Therefore, PTR per unit | 5.51x(1-62.23%) | 2.08 | -- | -- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.33 | -- | -- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 2.41 | S.O. 2104 | -- | -- | -- | ||
| Source of Data-IMS( Dec, 2013) | |||||||||
| S.No. | Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Azulix 4 MF Each uncoated bilayered tablet contains: Glimepiride IP 4 mg Metformin Hydrochloride IP 500 mg (in sustained release form) |
Zoryl-M | Intas | Tablet | 10 | 97.28 | 5,878,926 | 100.00% | 9.73 |
| -- | Monopoly situation as only M/s. In | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | -- | 9.73 | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-sect | -- | -- | -- | -- | -- | -- | -- | -- |
| 18.5: Medicines used in Diabetes mellitus |
-- |
||||||||
| 18.5.1: Insulins and other Antidiabetic agents |
-- |
||||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Metformin | P, S, T | Tablets | 500 mg | 1.56 | 2nd | 1814 | 21.6.2013 | 41.56 |
| -- | -- | -- | -- | -- | -- | -- | -- | Average Reduction | 41.56 |
| -- | Therefore, PTR per unit | 9.73x(1-41.56%) | 5.69 | -- | -- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.91 | -- | -- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 6.60 | S.O. 2105 | -- | -- | -- | ||
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | -- | -- | -- | -- | Source of Data-IMS( Dec, 2013) | -- | -- | -- | -- |
| S.No. | Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Azulix 3 MF Each uncoated bilayered tablet contains: Glimepiride IP 3 mg Metformin Hydrochloride IP 500 mg (in sustained release form) |
Zoryl-M | Intas | Tablet | 10 | 68.46 | 9,733,156 | 100.00% | 6.85 |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | Monopoly situation as only M/s. In | -- | -- | -- | -- | -- | -- | -- | -- |
| -- | PTR per unit | -- | -- | 6.85 | -- | -- | -- | -- | -- |
| -- | Price fixed in the relevant sub-sect | -- | -- | -- | -- | -- | -- | -- | -- |
| 18.5: Medicines used in Diabetes mellitus |
-- |
||||||||
| 18.5.1: Insulins and other Antidiabetic agents |
-- |
||||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Metformin | P, S, T | Tablets | 500 mg | 1.56 | 2nd | 1814 | 21.6.2013 | 41.56 |
| -- | -- | -- | -- | -- | -- | -- | -- | Average Reduction | 41.56 |
| -- | Therefore, PTR per unit | 6.85x(1-41.56%) | 4.00 | -- | -- | -- | -- | ||
| -- | Add: 16% Retailer Margin | -- | 0.64 | -- | -- | -- | -- | ||
| -- | Ceiling Price per unit | -- | 4.64 | S.O. 2105 | -- | -- | -- | ||
Last Page Updated: 15-01-2019
Copyright © 2023 - All Rights Reserved- Official Website of National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Government of India
Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)